Advertisement
enGene Inc. Warrants (ENGNW)
NASDAQ: ENGNW
· Real-Time Price · USD
0.70
-0.02 (-2.78%)
At close: Apr 28, 2025, 2:28 PM
-2.78% (1D)
Bid | n/a |
Market Cap | 35.69M |
Revenue (ttm) | n/a |
Net Income (ttm) | n/a |
EPS (ttm) | n/a |
PE Ratio (ttm) | n/a |
Forward PE | n/a |
Analyst | n/a |
Ask | n/a |
Volume | 1 |
Avg. Volume (20D) | 7,742.635 |
Open | 0.71 |
Previous Close | 0.72 |
Day's Range | 0.70 - 0.71 |
52-Week Range | 0.70 - 0.71 |
Beta | -0.37 |
About ENGNW
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calm...
Industry Biotechnology
Sector Healthcare
IPO Date n/a
Employees 56
Stock Exchange NASDAQ
Ticker Symbol ENGNW